Intravenous injection of leconotide, an omega conotoxin: Synergistic antihyperalgesic effects with morphine in a rat model of bone cancer pain

Pain Medicine

Volumn 12, Issue 6, 2011, Pages 923-941

  Kolosov, Anton ^a   Aurini, Lucia ^a   Williams, Elizabeth D ^a   Cooke, Ian ^b   Goodchild, Colin S ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Bone Cancer Pain; Hyperalgesia; Intravenous Injection; Morphine; Synergy; Conopeptide

Indexed keywords

MORPHINE; OMEGA CONOTOXIN CVID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE CANCER; CANCER PAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; HYPERALGESIA; MALE; NONHUMAN; PAIN THRESHOLD; RAT; TREATMENT OUTCOME;

EID: 79959244402     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2011.01118.x     Document Type: Article

References (59)

1. American Cancer Society. Cancer Facts and Figures. Atlanta, GA: Author; 2008.
2. Australian Institute of Health and Welfare (AIHW) & Australasian Association of Cancer Registries (AACR). Cancer in Australia: An Overview, 2006. Canberra: AIHW; 2007.
3. Australian Institute of Health Welfare, Cancer Australia & Australasian Association of Cancer Registries. Cancer survival and prevalence in Australia: Cancers diagnosed from 1982 to 2004. 2008; Cancer Series no. 42 (Cat. no. CAN 38).
4. Coleman RE, Purohit OP, Vinholes JJ, Zekri J. High dose pamidronate: Clinical and biochemical effects in metastatic bone disease. Cancer 1997;80:1686-90.
5. De S, Chen J, Narizhneva NV, etal. Molecular pathway for cancer metastasis to bone. J Biol Chem 2003;278:39044-50.
6. Horvath G, Kekesi G, Dobos I, Klimscha W, Benedek G. Long-term changes in the antinociceptive potency of morphine or dexmedetomidine after a single treatment. Anesth Analg 2005;101:812-8.
7. Mercadante S, Radbruch L, Caraceni A, etal. Episodic (breakthrough) pain-Consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002;94:832-9.
8. Scott DA, Wright CE, Angus JA. Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. Eur J Pharmacol 2002;451:279-86.
9. Smith MT, Cabot PJ, Ross FB, Robertson AD, Lewis RJ. The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain 2002;96:119-27.
10. Norton RS, Pallaghy PK, Baell JB, etal. Polypeptide omega-conotoxin GVIA as a basis for new analgesic and neuroprotective agents. Drug Dev Res 1999;46:206-18.
11. Klotz U. Ziconotide-A novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain-A short review. Int J Clin Pharmacol Ther 2006;44:478-83.
12. Wallace MS, Kosek PS, Staats P, etal. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: Addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med 2008;9:271-81.
13. Williams JA, Day M, Heavner JE. Ziconotide: An update and review. Expert Opin Pharmacother 2008;9:1575-83.
14. McGuire D, Bowersox S, Fellmann JD, Luther RR. Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: First demonstration of N-channel function in humans. J Cardiovasc Pharmacol 1997;30:400-3.
15. Penn RD, Paice JA. Adverse effects associated with the intrathecal administration of ziconotide. Pain 2000;85:291-6.
16. Pruneau D, Angus JA. Omega-conotoxin GVIA, the N-type calcium channel inhibitor, is sympatholytic but not vagolytic: Consequences for hemodynamics and autonomic reflexes in conscious rabbits. J Cardiovasc Pharmacol 1990;16:675-80.
17. Pruneau D, Angus JA. Omega-conotoxin GVIA is a potent inhibitor of sympathetic neurogenic responses in rat small mesenteric arteries. Br J Pharmacol 1990;100:180-4.
18. Lewis RJ, Nielsen KJ, Craik DJ, etal. Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J Biol Chem 2000;275:35335-44.
19. Wright CE, Robertson AD, Whorlow SL, Angus JA. Cardiovascular and autonomic effects of omega-conotoxins MVIIA and CVID in conscious rabbits and isolated tissue assays. Br J Pharmacol 2000;131:1325-36.
20. Bowersox SS, Singh T, Luther RR. Selective blockade of N-type voltage-sensitive calcium channels protects against brain injury after transient focal cerebral ischemia in rats. Brain Res 1997;747:343-47.
21. Wang YX, Bowersox SS. Analgesic properties of ziconotide, a selective blocker of N-type neuronal calcium channels. CNS Drug Rev 2000;6:1-20.
22. Zimmerman M. Ethical guidelines for investigation of experimental pain on conscious animals. Pain 1983;16:109-10.
23. Bureau of Animal Welfare. Code of practice for the use of animals from municipal pounds in scientific procedures. Government Gazette 2001 (AG0766):1-2.
24. Medhurst SJ, Walker K, Bowes M, etal. A rat model of bone cancer pain. Pain 2002;96:129-40.
25. Zhang RX, Liu B, Wang L, etal. Spinal glial activation in a new rat model of bone cancer pain produced by prostate cancer cell inoculation of the tibia. Pain 2005;118:125-36.
26. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988;32:77-88.
27. Randall LO, Selitto JJ. A method for measurement of analgesic activity of inflamed tissue. Arch Int Pharmacodyn Ther 1957;111:409-19.
28. Winter L, Nadeson R, Tucker AP, Goodchild CS. Antinociceptive properties of neurosteroids: A comparison of alphadolone and alphaxalone in potentiation of opioid antinociception. Anesth Analg 2003;97:798-805.
29. Kolosov A, Goodchild CS, Cooke I. CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: A comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med 2010;11:262-73.
30. Gerold M, Tschirky H. Measurement of blood pressure in unanaesthetized rats. Arzneimittelforschung 1968;18:1285-7.
31. Pfeffer JM, Pfeffer MA, Frohlich ED. Validity of an indirect tail-cuff method for determining systolic arterial pressure in unanesthetized normotensive and spontaneously hypertensive rats. J Lab Clin Med 1971;78:957-62.
32. Matsuda S, Kurokawa K, Higuchi K, etal. A new blood pressure measuring apparatus equipped with a microcomputer system for conscious rats. J Pharmacol Methods 1987;17:361-76.
33. Mach DB, Rogers SD, Sabino MC, etal. Origins of skeletal pain: Sensory and sympathetic innervation of the mouse femur. Neuroscience 2002;113:155-66.
34. Wacnik PW, Kehl LJ, Trempe TM, etal. Tumor implantation in mouse humerus evokes movement-related hyperalgesia exceeding that evoked by intramuscular carrageenan. Pain 2003;101:175-86.
35. Seong J, Park HC, Kim J, Kim UJ, Lee BW. Radiation-induced alteration of pain-related signals in an animal model with bone invasion from cancer. Ann N Y Acad Sci 2004;1030:179-86.
36. Peters CM, Lindsay TH, Pomonis JD, etal. Endothelin and the tumorigenic component of bone cancer pain. Neuroscience 2004;126:1043-52.
37. Zhao C, Wacnik PW, Tall JM, etal. Analgesic effects of a soy-containing diet in three murine bone cancer pain models. J Pain 2004;5:104-10.
38. Honore P, Schwei J, Rogers SD, etal. Cellular and neurochemical remodeling of the spinal cord in bone cancer pain. Prog Brain Res 2000;129:389-97.
39. Cain DM, Wacnik PW, Eikmeier L, etal. Functional interactions between tumor and peripheral nerve in a model of cancer pain in the mouse. Pain Med 2001;2:15-23.
40. Tallarida RJ, Raffa RB. Testing for synergism over a range of fixed ratio drug combinations: Replacing the isobologram. Life Sci 1996;58:PL 23-8.
41. Grabovsky Y, Tallarida RJ. Isobolographic analysis for combinations of a full and partial agonist: Curved isoboles. J Pharmacol Exp Ther 2004;310:981-6.
42. King AP, Hall KE, Macdonald RL. Kappa- and mu-opioid inhibition of N-type calcium currents is attenuated by 4beta-phorbol 12-myristate 13-acetate and protein kinase C in rat dorsal root ganglion neurons. J Pharmacol Exp Ther 1999;289:312-20.
43. Moises HC, Rusin KI, Macdonald RL. Mu- and kappa-opioid receptors selectively reduce the same transient components of high-threshold calcium current in rat dorsal root ganglion sensory neurons. J Neurosci 1994;14:5903-16.
44. Motin L, Yasuda T, Schroeder CI, Lewis RJ, Adams DJ. Omega-conotoxin CVIB differentially inhibits native and recombinant N- and P/Q-type calcium channels. Eur J Neurosci 2007;25:435-44.
45. Motin L, Adams DJ. Omega-conotoxin inhibition of excitatory synaptic transmission evoked by dorsal root stimulation in rat superficial dorsal horn. Neuropharmacology 2008;55:860-4.
46. Honore P, Luger NM, Sabino MA, etal. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000;6:521-8.
47. Honore P, Rogers SD, Schwei MJ, etal. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 2000;98:585-98.
48. Schwei MJ, Honore P, Rogers SD, etal. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 1999;19:10886-97.
49. Mantyh PW, DeMaster E, Malhotra A, etal. Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. Science 1995;268:1629-32.
50. Moises HC, Rusin KI, Macdonald RL. Mu-opioid receptor-mediated reduction of neuronal calcium current occurs via a G(o)-type GTP-binding protein. J Neurosci 1994;14:3842-51.
51. Newton RA, Bingham S, Case PC, Sanger GJ, Lawson SN. Dorsal root ganglion neurons show increased expression of the calcium channel alpha2delta-1 subunit following partial sciatic nerve injury. Brain Res Mol Brain Res 2001;95:1-8.
52. Abe M, Kurihara T, Han W, Shinomiya K, Tanabe T. Changes in expression of voltage-dependent ion channel subunits in dorsal root ganglia of rats with radicular injury and pain. Spine (Phila Pa 1976) 2002;27:1517-24.
53. Luo ZD, Calcutt NA, Higuera ES, etal. Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther 2002;303:1199-205.
54. Xiao HS, Huang QH, Zhang FX, etal. Identification of gene expression profile of dorsal root ganglion in the rat peripheral axotomy model of neuropathic pain. Proc Natl Acad Sci U S A 2002;99:8360-5.
55. Li CY, Song YH, Higuera ES, Luo ZD. Spinal dorsal horn calcium channel alpha2delta-1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. J Neurosci 2004;24:8494-9.
56. Field MJ, Hughes J, Singh L. Further evidence for the role of the alpha(2)delta subunit of voltage dependent calcium channels in models of neuropathic pain. Br J Pharmacol 2000;131:282-6.
57. Nielsen KJ, Schroeder T, Lewis R. Structure-activity relationships of omega-conotoxins at N-type voltage-sensitive calcium channels. J Mol Recognit 2000;13:55-70.
58. Mould J, Yasuda T, Schroeder CI, etal. The alpha2delta auxiliary subunit reduces affinity of omega-conotoxins for recombinant N-type (Cav2.2) calcium channels. J Biol Chem 2004;279:34705-14.
59. Sharp D. Novel pain relief via marine snails. Lancet 2005;366:439-40.